Pharmsintez and LDA Capital Group have entered into an agreement that will help fund the company's projects, including those aimed at combating COVID-19. Both companies see the capital allocation not only as an investment in the company, but also as a possible partnership to advance Pharmsintez's projects in developing treatments for complex diseases. LDA Capital will allocate up to ₽800 million.